Dow Fights Back Into the Green on Good Coke, J&J Numbers
A big day for blue-chip earnings may be helping the Dow Jones Industrial Average move out of red territory and up 32 points as of 2:30 p.m. EDT. Renewed fears over possible escalation in the ongoing Ukraine-Russia standoff had sent jitters across the investment landscape for much of the day, as Dow components Coca-Cola and Johnson & Johnson rose following their respective first-quarter earnings reports. Let's catch up on what you need to know.
Coca-Cola's fizzy results
Coca-Cola's stock rocketed higher by 3.9%, leading all Dow stocks, after its big earnings day. The company's revenue disappointed investors by slumping 4%, but that was still enough to top analyst expectations. Meanwhile, Coke's adjusted earnings of $0.44 per share landed squarely on projections. More importantly, worldwide case volume jumped by 2% -- also topping analyst projections.
Geographic differences made a big impact in the quarter. While volume fell 4% in Europe, Coca-Cola saw volume climb by 12% in China and 9% in Russia, the latter result helped by the company's presence around the Olympic Games in Sochi. With attitudes toward soda falling in advanced economies such as Europe and the U.S., the company will need to keep fueling growth in China, Russia, and other developing nations. Soda volume fell by 1% for the quarter in North America, and while Coca-Cola has done a good job diversifying its product portfolio into drinks such as bottled water and other nonsoda items, geographic diversity will be its most important weapon in keeping volume growing.
Johnson & Johnson is also riding earnings optimism today despite the Dow's drop, as the diversified health-care giant's stock jumped 1.8%. An 8% earnings climb kicked off J&J's big day, with revenue gaining 3.5% in a first quarter marked by a huge jump from the company's pharmaceutical business. That was enough to convince Johnson & Johnson to increase its earnings forecast for 2014 by $0.05 to both its high and low ends.
While the 11% spike in J&J's drug sales has kept the stock moving today, it's no surprise to investors who have watched the pharmaceutical business emerge as Johnson & Johnson's highest-grossing segment. New hepatitis C drug Olysio, which U.S. regulators approved just last November, pulled in more than $350 million in quarterly revenue. The hepatitis C market has exploded with contenders recently, and investors shouldn't get too optimistic about Olysio given the tight race for the new all-oral hep C market between numerous pharma and biotech giants. However, Olysio has surprised so far, and there's no reason to think it can't carve out a successful and profitable niche in the market. Considering that Johnson & Johnson's drug business has years to ride the patent of top seller Remicade, which hauled in more than $6 billion in sales last year, investors should expect the company to remain on top.
You can't afford to miss out on the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and it's ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.
The article Dow Fights Back Into the Green on Good Coke, J&J Numbers originally appeared on Fool.com.Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Coca-Cola and Johnson & Johnson. The Motley Fool owns shares of Coca-Cola and Johnson & Johnson and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.